LifeMD Inc

LifeMD Inc(LFMD)股票分析

$2.290

-0.150 (-6.53%)收盤時

Loading chart…
最高
2.490
開盤
2.460
成交量加權均價
2.33
成交量
597.21K
市值
279.29M
最低
2.205
成交金額
1.39M
企業價值/稅息折舊攤銷前利潤(TTM)
-3.54

LifeMD, Inc. is a patient-centric, direct-to-patient healthcare company. The Company is engaged in providing patients access to virtual medical care and pharmacy services. Its telehealth platform helps patients access licensed providers for diagnoses, virtual care, and prescription medications, often delivered on a recurring basis and sells over the counter (OTC) products. Its products are available on a subscription or membership basis, where a patient can subscribe to receive regular shipments of prescribed medications or products. The Company's men's brand, RexMD, offers access to virtual medical treatment for a variety of men's health needs, including erectile dysfunction, premature ejaculation and hair loss. Its vertically integrated care model combines technology, affiliated clinical services, pharmacy infrastructure, and artificial intelligence (AI)-enabled operational systems to deliver longitudinal care.

AI 分析 of LifeMD Inc (LFMD)

買進

LifeMD Inc appears to be a good buy right now due to its current price of $2.31, which is significantly below its 52-week high of $5.73, indicating potential for upside. The stock has a forward P/E ratio of 12.85, suggesting it may be undervalued compared to future earnings. Additionally, the RSI is at 55.54, indicating the stock is neither overbought nor oversold, which is a favorable technical indicator. However, the main risk is the company's net income, which has been negative, with a reported loss of $9.64 million in Q1 2026, highlighting ongoing financial challenges.

估值指標

LifeMD Inc(LFMD)目前預期本益比為 12.85,5 年平均預期本益比為 -15.58。

預期本益比

合理
5 年均值 P/E
-15.58
目前P/E
12.85
高估
43.95
低估
-75.10

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
5.86
目前EV/EBITDA
-3.54
高估
18.37
低估
-6.64

預期股價營收比

低估
5 年均值 P/S
0.93
目前P/S
0.48
高估
1.37
低估
0.49

Alphio AI 對 LFMD 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%LFMD

$14.58

情境價格

基

基準

基準 · 50%LFMD

$13.42

情境價格

悲

悲觀

悲觀 · 25%LFMD

$9.37

情境價格

事件時間軸

2026-11-05 (ET)

10:00:00

LifeMD Partners with Eli Lilly for Direct GLP-1 Drug Dispensing

2026-09-17 (ET)

12:00:00

H.C. Wainwright Gives LifeMD Buy Rating, Price Target $9

2026-08-05 (ET)

18:30:00

LifeMD Sees Q3 Adjusted EBITDA Loss of $1M to Gain of $2M

18:30:00

LifeMD Cuts FY26 Revenue Outlook to $6B Loss

資訊

LFMD 常見問題 —— 由 Alphio AI 解答

LifeMD, Inc. is a patient-centric, direct-to-patient healthcare company. The Company is engaged in providing patients access to virtual medical care and pharmacy services. Its telehealth platform helps patients access licensed providers for diagnoses, virtual care, and prescription medications, often delivered on a recurring basis and sells over the counter (OTC) products. Its products are available on a subscription or membership basis, where a patient can subscribe to receive regular shipments of prescribed medications or products. The Company's men's brand, RexMD, offers access to virtual medical treatment for a variety of men's health needs, including erectile dysfunction, premature ejaculation and hair loss. Its vertically integrated care model combines technology, affiliated clinical services, pharmacy infrastructure, and artificial intelligence (AI)-enabled operational systems to deliver longitudinal care. It operates in the Healthcare sector (SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE industry).

LifeMD Inc appears to be a good buy right now due to its current price of $2.31, which is significantly below its 52-week high of $5.73, indicating potential for upside. The stock has a forward P/E ratio of 12.85, suggesting it may be undervalued compared to future earnings. Additionally, the RSI is at 55.54, indicating the stock is neither overbought nor oversold, which is a favorable technical indicator. However, the main risk is the company's net income, which has been negative, with a reported loss of $9.64 million in Q1 2026, highlighting ongoing financial challenges.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易